NEW YORK (GenomeWeb News) - An investment banks today upgraded Invitrogen’s stock despite missed second-quarter estimates and revised forecasts.
 
An analyst at Banc of America Securities upgraded the shares to “Buy” from “Neutral” and said the company “will begin to benefit” from the two-year investment in research and development and facility expansions.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.